FGFR2

Across TCGA pan-cancer cohorts, FGFR2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FGFR2 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher FGFR2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FGFR2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

BRCA, LUSC, and UCEC are the cancer types where FGFR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	III,IV	0.233	0.833	.004	12	view →
LUSC	DFS	Median	III,IV	0.079	0.658	<.001	12	view →
UCEC	DFS	Median	II,III,IV	0.871	0.428	.018	10	view →
LIHC	OS	Median	III,IV	0.255	0.652	.012	6	view →
SKCM	OS	Median	All	0.975	0.864	.010	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FGFR2–BRCA (OS)

Open the BRCA breakdown →